---
title: "InnoCare says Phase II vitiligo trial of TYK2 inhibitor soficitinib meets primary endpoint at Week 24"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292878542.md"
description: "InnoCare Pharma announced that its Phase II trial for the oral TYK2 inhibitor soficitinib in non-segmental vitiligo met its primary endpoint at Week 24. The study demonstrated meaningful improvement in facial repigmentation compared to placebo, with a safety profile consistent with prior data. Detailed results will be presented at upcoming congresses and submitted to journals. The ongoing Phase II/III adaptive trial plans regulatory discussions to support next-stage development."
datetime: "2026-07-16T08:51:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292878542.md)
  - [en](https://longbridge.com/en/news/292878542.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292878542.md)
generator: "portal-rs"
---

# InnoCare says Phase II vitiligo trial of TYK2 inhibitor soficitinib meets primary endpoint at Week 24

-   InnoCare Pharma reported positive topline Phase II results for oral TYK2 inhibitor soficitinib (ICP-332) in non-segmental vitiligo on July 16, 2026. \* The study met its primary goal, showing meaningful improvement versus placebo in facial repigmentation measures. \* Safety was consistent with prior studies, with no new safety signals flagged. \* Detailed Phase II data have not yet been presented; results will be shown at upcoming international congresses and submitted to a peer-reviewed journal. \* The Phase II/III adaptive trial continues, with plans to discuss the Phase II package with regulators to support next-stage development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12246490), on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic Dermatitis](https://longbridge.com/en/news/292764461.md)
- [InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory Filing](https://longbridge.com/en/news/293910253.md)
- [Abbisko unit Abbisko Therapeutics doses first patient in Phase I trial of pan-KRAS inhibitor ABSK211](https://longbridge.com/en/news/297476007.md)
- [FDA Clears First Targeted Dermatomyositis Treatment From Roivant](https://longbridge.com/en/news/297552522.md)
- [Weekly Recap: ALKIVIA Phase 3 VYVGART 52-week high and Forte adds FB102](https://longbridge.com/en/news/297465373.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**